Evidence map›Paper›PMID 27068708›Full record

Trial reportNature communications2016

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Helen A Fletcher, Margaret A Snowden, Bernard Landry, Wasima Rida, Iman Satti, Stephanie A Harris, Magali Matsumiya, Rachel Tanner, Matthew K O'Shea, Veerabadran Dheenadhayalan and 20 more

Erratum issuedOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 181 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 2 pooled it
30.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 2 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Influence of polyfunctional TbetFrontiers in immunology · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. HowVaccines · 2026
    Review

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 7 institutions in 3 countries.

Helen A FletcherJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Margaret A SnowdenAeras, Rockville, Maryland 20850, USA.
Bernard LandryAeras, Rockville, Maryland 20850, USA.
Wasima RidaBiostatistics Consultant, 1129 N. Illinois Street, Arlington, Virginia 22205, USA.ORCID 0000-0001-7671-7305
Iman SattiJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Stephanie A HarrisJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Magali MatsumiyaJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Rachel TannerJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Matthew K O'SheaJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Veerabadran DheenadhayalanAeras, Rockville, Maryland 20850, USA.
Leah BogardusAeras, Rockville, Maryland 20850, USA.
Lisa StockdaleJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Leanne MarsayOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK.
Agnieszka ChomkaKennedy Institute, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LF, UK.
Rachel Harrington-KandtJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Zita-Rose Manjaly-ThomasJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Vivek NaranbhaiWellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX37BN, UK.
Elena StylianouJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
Fatoumatta DarboeSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Gregory HusseySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Hassan MahomedSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Michele TamerisSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
J Bruce McClainAeras, Rockville, Maryland 20850, USA.
Thomas G EvansAeras, Rockville, Maryland 20850, USA.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Department of Paediatrics and Child Health, University of Cape Town, Cape Town 7935, South Africa.
Helen McShaneJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
University of Oxford · GBUniversity of Cape Town · ZAAeras · USUniversity of London · GBCentre for Human Genetics · GBNational Science Teachers Association · USNuffield Orthopaedic Centre · GB

Funding

Host determinants of protection against tuberculosis in adolescentsR01AI087915 · NIAID · UNIVERSITY OF CAPE TOWN · PI SCRIBA, THOMAS JENS · 2011 to 2015
$3.3M
NIAID NIH HHS R01 AI087915NIAID NIH HHS R01-AI087915Wellcome Trust
6 · The paper itself

Abstract

Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case-control analysis to identify immune correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A efficacy trial. Among 53 TB case infants and 205 matched controls, the frequency of activated HLA-DR(+) CD4(+) T cells associates with increased TB disease risk (OR=1.828, 95% CI=1.25-2.68, P=0.002, FDR=0.04, conditional logistic regression). In an independent study of Mycobacterium tuberculosis-infected adolescents, activated HLA-DR(+) CD4(+) T cells also associate with increased TB disease risk (OR=1.387, 95% CI=1.068-1.801, P=0.014, conditional logistic regression). In infants, BCG-specific T cells secreting IFN-γ associate with reduced risk of TB (OR=0.502, 95% CI=0.29-0.86, P=0.013, FDR=0.14). The causes and impact of T-cell activation on disease risk should be considered when designing and testing TB vaccine candidates for these populations.

Indexed as

VaccinationAdolescentAntibody FormationBCG VaccineCase-Control StudiesCD4-Positive T-LymphocytesCohort StudiesHLA-DR AntigensHumansImmunityImmunoglobulin GInfantLogistic ModelsLymphocyte ActivationMycobacterium tuberculosisPlacebosBCG VaccineHLA-DR AntigensImmunoglobulin GMVA 85APlacebosTuberculosis VaccinesVaccines, DNA

Identifiers

PMID27068708
PMCPMC4832066
OpenAlexW2340217599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.